Rita Murri, MD; Adriana Ammassari, MD; Andrea Antinori, MD
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
Murri R., Ammassari A., Antinori A.; Adherence to Protease Inhibitors. Ann Intern Med. 2001;134:625. doi: 10.7326/0003-4819-134-7-200104030-00019
Download citation file:
Published: Ann Intern Med. 2001;134(7):625.
TO THE EDITOR:
In an excellent paper, Paterson and colleagues (1) demonstrate that adherence to protease inhibitor therapy of 95% or greater optimizes virologic outcome for patients with HIV infection. In our opinion, however, this conclusion cannot be generalized to all HIV-infected patients, especially those who were previously treated with antiretroviral agents.
We performed a prospective cohort study on adherence to antiretroviral agents in 140 consecutive HIV-infected patients who were attending the outpatient service of the Department of Infectious Diseases, Catholic University of Rome, Rome, Italy, and were taking a regimen containing protease inhibitors. Median duration of antiretroviral therapy was 43 months (range, 2 to 121 months). Seventy-seven percent of patients had previously received one or more other antiretroviral regimens, and 89% had been taking a protease inhibitor for at least 3 months. Nonadherence was assessed by questionnaire-based patient self-report and was defined as having missed at least one antiretroviral dose during the previous week. The validity of this simple, cheap, well-accepted, and feasible method has been shown (2).
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only